TCR-T: A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma

* Histologically or cytologically confirmed Hepatocellular carcinoma (HCC)

* Subjects with HCC who have received at least 2 standard systemic therapies

* HLA-A *02

* BCLC stage B or C

* Child-pugh score ≤ 7

* Serum HBeAg negative, serum (or tumor tissue) HBsAg positive, and serum HBV-DNA must be 2 × 1000 IU/ml

* Have at least one measurable leasion at baseline as per mRECIST and RECIST v1.1 criteria

* Life expectancy of 3 months or greater

* Ability to provide informed consent form

* Ability to comply with all the study procedures

* Subjects with history of another primary cancer

* Untreated or active central nervous system (CNS) or leptomeningeal metastasis, or history of hepatic encephalopathy, or other clinically significant CNS diseases

* Autoimmune diseases requiring immunosuppressive therapy (except topical medication) or subjects with significant persistent immune rejection

* Known history of neurological or mental disorder, including epilepsy or dementia

* Known history of positive results for human immunodeficiency virus (HIV) 1 or 2 or known acquired immunodeficiency syndrome (AIDS)

* Prior exposure to any cell therapy such as, but not limited to killer (NK) cells, cytokine-induced killer (CIK) cells, dendritic cells (DC), cytotoxic T lymphocytes (CTL), stem cell therapy, CAR T/TCR T cell therapy

* Allergy to immunotherapy drugs and lymphodepleting chemotherapy (cyclophosphamide and fludarabine)

* Any subjects who cannot be evaluated by either triphasic liver CT or triphasic MRI because of allergy or other contraindication to both CT and MRI contrast agents

* Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation